Daily Stock Analysis, ARWR, Arrowhead Pharmaceuticals Inc, priceseries

Arrowhead Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
26.29
Close
27.15
High
27.21
Low
25.95
Previous Close
26.29
Daily Price Gain
0.86
YTD High
28.84
YTD High Date
Jun 27, 2019
YTD Low
11.67
YTD Low Date
Jan 2, 2019
YTD Price Change
14.03
YTD Gain
106.94%
52 Week High
28.84
52 Week High Date
Jun 27, 2019
52 Week Low
10.41
52 Week Low Date
Dec 24, 2018
52 Week Price Change
10.74
52 Week Gain
65.45%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 14. 2017
2.01
Mar 6. 2017
2.14
13 Trading Days
6.52%
Link
LONG
Aug 11. 2017
1.84
Sep 14. 2017
2.92
23 Trading Days
58.54%
Link
LONG
Sep 22. 2017
3.55
Oct 10. 2017
4.05
12 Trading Days
14.08%
Link
LONG
Jan 2. 2018
3.72
Feb 2. 2018
5.87
22 Trading Days
57.71%
Link
LONG
Feb 23. 2018
5.80
Mar 19. 2018
7.13
16 Trading Days
22.90%
Link
LONG
May 2. 2018
7.14
Jun 7. 2018
10.15
25 Trading Days
42.16%
Link
LONG
Jun 29. 2018
13.60
Jul 20. 2018
16.08
14 Trading Days
18.25%
Link
LONG
Jan 4. 2019
13.18
Jan 22. 2019
13.91
11 Trading Days
5.54%
Link
LONG
Feb 8. 2019
15.66
Mar 6. 2019
18.80
17 Trading Days
20.06%
Link
LONG
May 21. 2019
21.35
Jun 14. 2019
25.92
17 Trading Days
21.42%
Link
Company Information
Stock Symbol
ARWR
Exchange
NasdaqGS
Company URL
http://www.arrowheadpharma.com
Company Phone
626-304-3400
CEO
Christopher Richard Anzalone
Headquarters
California
Business Address
225 SOUTH LAKE AVENUE, SUITE 1050, PASADENA, CA 91101
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000879407
About

Arrowhead Pharmaceuticals, Inc. engages as a biopharmaceutical company developing targeted RNAi therapeutics. Its pipeline includes clinical programs in chronic hepatitis B virus and partner based programs in obesity and oncology. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Description

Arrowhead Pharmaceuticals, Inc. develops novel drugs to treat intractable diseases in the United States. Its pre-clinical stage drug candidates include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency; ARO-LPA to reduce production of apolipoprotein A; ARO-AMG1, which is developed against an undisclosed genetically validated cardiovascular target; and ARO-F12, a potential treatment for factor 12 mediated diseases, such as hereditary angioedema and thromboembolic disorders. The company also develops ARO-HIF2, a drug candidate for the treatment of clear cell renal cell carcinoma. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreements with Amgen, Inc. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.